Events
News
- July 12, 2010
THALLION ANNOUNCES 2010 SECOND QUARTER RESULTS
- June 24, 2010
THALLION ELIMINATES LONG-TERM LEASE OBLIGATION
- June 16, 2010
THALLION PHARMACEUTICALS RECEIVES ARBITRATION DECISION ON TLN-232 LICENSE AGREEMENT

Thallion Pharmaceuticals Inc. is a biotechnology company focussed on developing new treatments for under-served markets in oncology and infectious disease.
THALLION ANNOUNCES 2010 SECOND QUARTER RESULTS
THALLION ELIMINATES LONG-TERM LEASE OBLIGATION
THALLION PHARMACEUTICALS RECEIVES ARBITRATION DECISION ON TLN-232 LICENSE AGREEMENT